Leukemia, Plasma Cell: all 60 studies

Page 1 of 1. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.

• QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingNCT07903623Phase 2
• CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingNCT07652905Phase 2
• Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingNCT07649525Phase 3
• Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialRecruitingNCT07605416Phase 2
• Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesRecruitingNCT07523555Phase 1/2
• IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell LeukemiaRecruitingNCT07509086Phase 2
• IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07185490Early Phase 1
• Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MMRecruitingNCT07109323Phase 1/2
• ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell LeukemiaRecruitingNCT07106684Phase 2
• Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical ResearchRecruitingNCT07085559Early Phase 1
• A Study of CT0596 in Plasma Cell LeukemiaRecruitingNCT06988059Early Phase 1
• The Norwegian Immunotherapy in Multiple Myeloma StudyRecruitingNCT06855121
• Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell LeukaemiaNot yet recruitingNCT06830733Phase 2
• A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell LeukemiaRecruitingNCT06730256Early Phase 1
• a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaRecruitingNCT06718270Early Phase 1
• An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaNot yet recruitingNCT06655519Phase 1
• An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll LRecruitingNCT06636552Phase 2
• Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple MyelomaRecruitingNCT06517017Phase 2
• European Myeloma Network (EMN) Sample ProjectRecruitingNCT06237803
• To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCLRecruitingNCT06045091Early Phase 1
• A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell LeukemiaRecruitingNCT05979363Phase 2
• Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05893693Not applicable
• CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05822037Not applicable
• Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
• A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05759793Phase 1
• Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme RegistryRecruitingNCT05556928
• Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell TransplantRecruitingNCT05405387Phase 2
• A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFHRecruitingNCT05283993
• A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05219721Phase 1
• Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
• Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell TransplantationNot yet recruitingNCT05054478Phase 2
• Registry for Adults With Plasma Cell Disorders (PCD's)RecruitingNCT03717844
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
• High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT03389347Not applicableResults posted
• UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 2Results posted
• Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT02506959Phase 2Results posted
• Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01729091Phase 2Results posted
• Carfilzomib and Stem Cell Transplant for Plasma Cell MyelomaTerminatedNCT01658904Phase 1/2Results posted
• Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT01008462Phase 2Results posted
• Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning RegimenTerminatedNCT00615589Phase 2Results posted
• Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell TransplantsCompletedNCT00307086Phase 2Results posted
• A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell LeukemiaActive, not recruitingNCT05870917Phase 2
• Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingNCT05823571Phase 1
• a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma PatientsStatus unknownNCT04008888Not applicable
• Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell LeukemiaWithdrawnNCT03591744Phase 1
• Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
• Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple MyelomaCompletedNCT02504359Phase 1
• SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyActive, not recruitingNCT02334865Phase 1
• Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple MyelomaWithdrawnNCT02315157Phase 1
• Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
• Lenalidomide and Dexamethasone in Primary Plasma Cell LeukemiaCompletedNCT01553357Phase 2
• Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)Status unknownNCT01435720Phase 1/2
• Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT01372540Phase 1
• Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell LeukemiaStatus unknownNCT01328236Phase 2
• A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01248923Phase 1
• Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple MyelomaCompletedNCT01163357Phase 1
• A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00821249Phase 1/2
• Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00027820Phase 1/2

← Leukemia, Plasma Cell overview